Saturday 17 October 2026
Export DMRA’s income statement to Excel — free account
Galecto, Inc.
DMRA Healthcare Biotechnology
In the quarter to June 2026, EPS grew 85.0% and free cash flow fell 877.5%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years; insiders bought in the last twelve months.
18.42
0.32
−1.71%
Follow DMRA
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | |
|---|---|---|---|---|---|---|---|---|---|
Current Ratio |
12.98 | 14.07 | 6.31 | 5.75 | 24.23 | 30.42 | 7.07 | 7.87 | — |
Net Debt/EBITDA |
1.22 | 0.64 | 0.83 | 0.99 | 1.96 | 4.86 | 0.29 | 2.40 | — |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Operating CF/Net income |
1.24 | 0.87 | 0.96 | 0.70 | 1.01 | 1.10 | 0.46 | 0.72 | — |
Capex/Depreciation |
0.00 | 0.00 | (0.51) | (0.32) | (0.20) | 0.00 | 0.00 | — | — |
Interest Coverage |
— | — | — | — | — | — | — | (8.69) | — |
| 6.72% | (91.62%) | (81.52%) | (68.86%) | (36.61%) | (73.85%) | 80.14% | 36.21% | — | |
| (3.90%) | (77.45%) | (68.84%) | (63.07%) | (35.23%) | (30.53%) | (91.74%) | (108.28%) | — | |
ROIC |
0.00% | (840.13%) | 0.00% | (2,501.92%) | (191.65%) | (1,102.42%) | (65.52%) | 0.00% | — |
Return on Tangible Assets |
(2.25%) | (136.56%) | (123.62%) | (115.92%) | (48.93%) | (21.16%) | (86.82%) | (62.28%) | — |
Average Days of Receivables |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — | — | — |
Free Cash Flow per Share |
(4.93) | (16.10) | (34.65) | (42.43) | (51.99) | (208.87) | (1,858.27) | (0.54) | — |
Cash per Share |
189.01 | 12.25 | 31.19 | 59.25 | 99.15 | 894.38 | 1,085.96 | 1.22 | — |
Shareholders Equity per Share |
176.36 | 13.68 | 30.41 | 60.76 | 116.00 | 904.81 | 4,660.67 | 1.21 | — |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Book value per Share |
176.36 | 13.68 | 30.41 | 60.76 | 116.00 | 904.81 | 4,660.67 | 1.21 | — |
Free Cash Flow |
(6.73) | (18.62) | (36.83) | (43.13) | (52.53) | (38.20) | (19.33) | (13.69) | — |
Working Capital |
240.36 | 15.64 | 30.94 | 52.80 | 105.56 | 163.73 | 48.15 | 30.52 | — |
Capital Expenditures |
— | — | 0.08 | (0.20) | (0.22) | — | — | — | — |
Net Current Asset Value |
240.28 | 15.54 | 30.88 | 52.48 | 105.11 | 163.19 | 47.94 | 30.52 | — |
| Other line items | |||||||||
Quick Ratio |
12.84 | 11.84 | 5.69 | 5.42 | 22.05 | 29.39 | 6.43 | 7.20 | — |
Depreciation/Fixed assets |
0.00 | 1.60 | (2.08) | 1.70 | 5.38 | 0.21 | 0.37 | — | — |
Cash ROIC |
(1.35%) | (62.06%) | (56.24%) | (35.36%) | (24.16%) | (11.61%) | (32.34%) | (22.21%) | — |
Accounts Receivable Turnover |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Inventory Turnover |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Days of Inventory on Hand |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Operating CF per Share |
(4.93) | (16.10) | (34.72) | (42.24) | (51.76) | (208.87) | (1,858.27) | (0.54) | — |
Capex per Share |
0.00 | 0.00 | 0.08 | (0.19) | (0.22) | 0.00 | 0.00 | 0.00 | — |
Average Receivables |
— | — | — | 1.83 | 2.24 | 20.94 | 20.33 | 21.06 | — |
Average Payables |
9.02 | 1.04 | 2.53 | 2.44 | 2.19 | 3.09 | 2.37 | 2.37 | — |
Average Assets |
138.83 | 27.68 | 55.71 | 97.70 | 146.91 | 114.10 | 45.86 | 17.55 | — |
Average Common Equity |
(80.70) | 23.40 | 47.04 | 89.49 | 141.36 | 47.17 | (52.49) | (52.49) | — |
Capex to Sales |
— | — | 0.00 | 0.00 | 0.00 | — | — | — | — |
Columns are period end dates